COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02203474
Recruitment Status : Withdrawn
First Posted : July 30, 2014
Last Update Posted : August 27, 2014
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products R&D, Inc. )

Brief Summary:
The primary objective of this study is to demonstrate the superiority of tiotropium hydrofluoroalkane (HFA) breath actuated inhaler (BAI) to placebo HFA BAI following repeated, once-daily dosing.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease COPD Drug: Tiotropium HFA BAI 5 mcg Drug: Tiotropium 18 mcg Capsule Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Double-Dummy, Parallel Group, Dose-Ranging Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), Placebo HFA BAI, and Open-Label SPIRIVA® HandiHaler® (18 mcg) in Patients With Chronic Obstructive Pulmonary Disease
Study Start Date : August 2014
Actual Primary Completion Date : August 2014
Actual Study Completion Date : August 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arm Intervention/treatment
Experimental: Tiotropium HFA BAI 5 mcg
1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
Drug: Tiotropium HFA BAI 5 mcg
Experimental: Tiotropium HFA BAI 10 mcg
1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
Drug: Tiotropium HFA BAI 5 mcg
Experimental: Tiotropium HFA BAI 15 mcg
1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
Drug: Tiotropium HFA BAI 5 mcg
Active Comparator: SPIRIVA HandiHaler
2 inhalations from one 18 mcg capsule daily
Drug: Tiotropium 18 mcg Capsule
Other Name: SPIRIVA HandiHaler

Placebo Comparator: Placebo
1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
Drug: Placebo

Primary Outcome Measures :
  1. FEV1 AUC0-24 [ Time Frame: Day 28 ]

Secondary Outcome Measures :
  1. FEV1 (AUC0-24) [ Time Frame: Day 1 ]
  2. Trough FEV1 [ Time Frame: Day 2 ]
  3. Percentage of patients with a COPD exacerbation [ Time Frame: 28 Days ]
  4. Percentage of Patients with Adverse Events [ Time Frame: 28 Days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patients 40 to 80 years of age, as of the screening visit (SV), who have signed an informed consent prior to initiation of any study related procedures.
  2. Diagnosis of COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.
  3. A measured post-bronchodilator (albuterol 360 mcg) forced expiratory volume in 1 second (FEV1) ≥30% and <80% of predicted normal at the SV. Predicted normal will be determined using National Health and Nutrition Examination Survey (NHANES) III standard values for Caucasians, African Americans and Mexican-Americans with adjustments to predicted values made for Asian American patients.
  4. A measured post-bronchodilator (albuterol 360 mcg) FEV1/forced vital capacity (FVC) <0.70 at the SV.
  5. A minimum body weight of 40 kg. (Note: For patients participating in the pharmacokinetic [PK] sub study a minimum body weight of 50 kg is required.)
  6. If female, is currently not pregnant, breast feeding, or attempting to become pregnant (for 4 weeks before the SV and throughout the duration of the study), and is of non-childbearing potential, defined as:

    • ≥1 year post-menopausal (6 months of spontaneous amenorrhea is permitted, provided there is a local record of serum follicle stimulating hormone >40 mIU/mL and this is source documented) or
    • Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, salpingectomy, or hysterectomy)

    Or is of childbearing potential, has a negative serum pregnancy test, and is willing to commit to using a consistent and acceptable method of birth control, as defined below, for the duration of the study:

    • Systemic contraception used for ≥1 month prior to screening, including birth control pills, transdermal patch, vaginal ring, implants, or injectables or
    • Double barrier methods (spermicide with any of the following: condoms, cervical cap, diaphragm, and vaginal contraceptive film) or
    • Intrauterine device (IUD) with a low failure rate defined as <1% per year (use of copper IUDs is not acceptable) Or is of childbearing potential and is not sexually active, has a negative serum pregnancy test, and, in the event the patient becomes sexually active, is willing to commit to using a consistent and acceptable method of birth control, as defined above, for the duration of the study. At the discretion of the investigator, total abstinence is acceptable in cases where the age, career (eg, priest), lifestyle, and/or sexual orientation of the patient ensures compliance.
  7. Current or ex-smoker with ≥10 pack-year smoking history (number of cigarette packs smoked per day multiplied by the number of years smoked; eg, 2 packs/day for 3 years equals a 6 pack-year history).
  8. Patient is free of any other medical conditions or concomitant treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the study.
  9. Able to perform technically acceptable and reproducible spirometry per American Thoracic Society/European Respiratory Society (ATS/ERS) 2005 guidelines and study guidelines, as defined in the protocol and study reference manual; this includes able to tolerate withdrawal of applicable medications during required spirometry assessments.
  10. Able to perform acceptable peak expiratory flow measurements.
  11. Able to maintain records (patient daily diary) during the study period as required by the protocol.
  12. Able to demonstrate the proper inhalation techniques required for correct use of all delivery devices (BAI and dry powder inhaler [DPI]) required in the study.
  13. Capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent and being compliant with all study requirements.

Exclusion Criteria:

Chronic Obstructive Pulmonary Disease

  1. Pregnancy, nursing, or plans to become pregnant or donate gametes (ova or sperm) for in vitro fertilization during the study period or for 30 days following the patient's last study related visit (for eligible patients only, if applicable).
  2. Current evidence of a clinically significant or uncontrolled disease including, but not limited to: cardiovascular (eg, uncontrolled hypertension, congestive heart failure, known aortic aneurysm, clinically significant cardiac arrhythmia or coronary heart disease), hepatic, renal, hematological, neuropsychological, endocrine (eg, uncontrolled diabetes mellitus, uncontrolled thyroid disorder, Addison's disease, Cushing's syndrome), gastrointestinal (eg, poorly controlled peptic ulcer, gastroesophageal reflux disease), or pulmonary (other than COPD such as asthma, sarcoidosis, non cystic fibrosis bronchiectasis, cystic fibrosis, bronchopulmonary dysplasia or a diagnosis of alpha 1 antitrypsin deficiency). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the patient at risk through participation, or which could affect the endpoint analysis if the disease/condition worsened during the study.
  3. History of and/or current diagnosis of asthma.
  4. History of a life-threatening COPD exacerbation - defined for this protocol as a COPD episode that required intubation or was associated with respiratory arrest.
  5. Thoracotomy with pulmonary resection.
  6. Current congestive heart failure, history or current evidence of myocardial infarction (within 1 year of the SV), or current history of active ischemic heart disease (exertional or intermittent angina).
  7. History or current evidence of clinically significant cardiac arrhythmia or abnormality, including a diagnosis on screening ECG. Findings that are always considered clinically significant and will exclude the patient from study participation include, but are not limited to, the following:

    • ventricular rate <45 beats per minute (bpm) or >100 bpm
    • PR interval >240 msec
    • evidence of 2nd- or 3rd-degree atrioventricular block (excluding MobitzI)
    • evidence of supraventricular or ventricular ectopy or arrhythmias
    • corrected QT interval (QTc) (Bazett's or Fridericia's method) >500 msec
    • nonspecific intraventricular conduction delay >120 msec
    • ST-T wave abnormalities (excluding nonspecific ST-T wave abnormalities) indicative of acute ischemia/infarction
    • right or left complete bundle branch block
    • artificial pacemaker
  8. The patient has a medical condition that may potentially be aggravated by an anticholinergic drug such as tiotropium, eg:

    • The patient has a history or presence of glaucoma (particularly angle-closure glaucoma)
    • The patient has symptomatic prostatic hyperplasia.
    • The patient has a known history or any current evidence of renal impairment or urinary retention (eg, bladder outlet obstruction). This includes abnormal renal function test results at screening.
  9. History of malignancy (excluding treated non-melanoma skin cancers) within the past 5 years, regardless of the clinical significance or current stability of the disease.
  10. History of silent (or active) infections, including positive tests for human immunodeficiency virus (HIV) 1, HIV2, hepatitis B, hepatitis C, or tuberculosis.
  11. Occurrence of any upper or lower respiratory infection, including but not limited to the common cold and flu, sinusitis, tonsillitis, pneumonia, bronchitis, or an ear infection (including otitis media and externa) which is not resolved by 4 weeks or more prior to the SV/informed consent.
  12. Occurrence of a COPD exacerbation which is not resolved by 4 weeks or more prior to the SV/informed consent.

    • Note: An exacerbation of COPD is defined as any worsening of the patient's baseline COPD symptoms requiring any treatment beyond study medication, rescue albuterol or the patient's regular maintenance treatment. This includes requiring the use of systemic corticosteroids, antibiotics and/or emergency room visit or hospitalization.

  13. Patients who require regular use of daytime oxygen therapy.
  14. Patients who have started or stopped an exercise rehabilitation program within 4 weeks of the SV.
  15. Known or suspected hypersensitivity or idiosyncratic reaction to tiotropium, or to any ingredients used in the study medication formulations.
  16. Severe allergy to milk protein.
  17. Significant adverse drug reactions, including allergy or hypersensitivity reactions, to atropine or any anticholinergic substance related pharmacologically to atropine (eg, ipratropium or oxitropium).
  18. Use of any prohibited concomitant medications within the required (per protocol) washout periods prior to the SV.
  19. Treatment with orally administered (excluding orally inhaled) β-adrenergic agonists (ie, oral albuterol).
  20. Recent initiation of treatment or dose titration with β-adrenergic receptor antagonists (eg, non-selective β-receptor blocking agents such as β-blocking anti-hypertensive products) administered by any route. Permitted exceptions are: (1) Patients treated on a stable dose of non-selective β-receptor blocking agents for 3 months prior to SV or longer may be considered for enrollment if expected to maintain the same dose throughout the study and (2) Patients on a stable dose of cardioselective β1 adrenergic receptor antagonists (eg, atenolol, metaprolol, bisoprolol) for at least 1 week prior to the SV are permitted if expected to maintain the same dose throughout the study.
  21. Treatment with drugs commonly recognized to prolong the QTc interval (eg, quinolones, amiodarone, disopyramide, quinidine, sotalol, chlorpromazine, haloperidol, ketoconazole, terfenadine, cisapride, and terodiline).
  22. Treatment with strong cytochrome P450 (CYP) 2D6 or CYP3A4 inducers or inhibitors (eg, quinidine, ketoconazole and gestodene) within 30 days prior to the SV.
  23. For patients using an inhaled corticosteroid, initiation or change in the dose of inhaled corticosteroids within the last 30 days prior to the SV, and/or the patient is not expected to maintain a stable dose of inhaled corticosteroids during the course of the study.
  24. For patients using maintenance oral corticosteroids for COPD, the average daily dose should not be greater than10 mg of prednisone equivalent per day and the dose should have been stable over the 6 weeks prior to the SV. The patient's prior oral corticosteroid (OCS) dose should be maintained without change during the study. (Note that oral steroid bursts completed 6 weeks or more prior to screening are acceptable.)
  25. Exposure to any investigational drug within 30 days or 6 half-lives (whichever is longer) prior to the SV.
  26. Has a history of alcohol and/or substance abuse within the past 5 years. aa. Vulnerable patients (eg, persons kept in detention). bb. The patient is an employee of the study site or has an immediate family member or household member involved with the conduct of the study (including participation in the study).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02203474

Sponsors and Collaborators
Teva Branded Pharmaceutical Products R&D, Inc.
Layout table for investigator information
Study Director: Teva Medical Expert, MD Teva Pharmaceuticals USA
Layout table for additonal information
Responsible Party: Teva Branded Pharmaceutical Products R&D, Inc. Identifier: NCT02203474    
Other Study ID Numbers: TBB-COPD-20009
First Posted: July 30, 2014    Key Record Dates
Last Update Posted: August 27, 2014
Last Verified: August 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Tiotropium Bromide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action